March 22, 2021 05:34 AM EDTUpdated 10:10 AM
R&D
Coronavirus

As­traZeneca read­ies April EUA fil­ing with 79% vac­cine ef­fi­ca­cy, first glimpse of el­der­ly da­ta and 100% pro­tec­tion against se­vere dis­ease in US tri­al

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times